CRN04894: an oral, nonpeptide adrenocorticotropic hormone (ACTH) receptor antagonist decreases basal and stimulated cortisol secretion in healthy volunteers
Peter Trainer(University of Manchester), Alan Krasner(Takeda (United States)), Struthers R. Scott, Christine Ferrara-Cook(Crinetics Pharmaceuticals (United States)), Stephen F. Betz(Abbott (United States)), Stephanie Miller(Hudson Institute of Medical Research), Rosa Luo(Crinetics Pharmaceuticals (United States)), Martha Hernandez‐Illas(San Diego Miramar College), Yang Wang(Beihang University), Alejandro Ayala(Instituto Tecnológico de Morelia)
Cited by 4
Related Papers
Treatment of Acromegaly with the Growth Hormone–Receptor Antagonist Pegvisomant
|New England Journal of Medicine|2000|874
Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist
|The Lancet|2001|643
Discovery of Potent Antagonists of the Antiapoptotic Protein XIAP for the Treatment of Cancer
|Journal of Medicinal Chemistry|2004|364
OFDM over indoor wireless optical channel
|IEE Proceedings - Optoelectronics|2005|185
Quantum corrections to the Weizsäcker-Williams gluon distribution function at small<i>x</i>
|Physical review. D. Particles, fields, gravitation, and cosmology/Physical review. D. Particles and fields|1996|182